Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
M Gacci, KE Andersson, C Chapple, M Maggi… - European urology, 2016 - Elsevier
Context Several preclinical reports, randomized controlled trials, systematic reviews, and
posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in …
posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in …
Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis
X Wang, X Wang, S Li, Z Meng, T Liu, X Zhang - PLoS One, 2014 - journals.plos.org
Introduction Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)
are common in elder men and a number of drugs alone or combined are clinically used for …
are common in elder men and a number of drugs alone or combined are clinically used for …
Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts
M Ammirante, S Shalapour, Y Kang… - Proceedings of the …, 2014 - National Acad Sciences
Prostate cancer (PC) is a slowly progressing malignancy that often responds to androgen
ablation or chemotherapy by becoming more aggressive, acquiring a neuroendocrine …
ablation or chemotherapy by becoming more aggressive, acquiring a neuroendocrine …
Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling
C Beyer, C Zenzmaier, K Palumbo-Zerr… - Annals of the …, 2015 - ard.bmj.com
Objectives We have previously described the antifibrotic role of the soluble guanylate
cyclase (sGC). The mode of action, however, remained elusive. In the present study, we …
cyclase (sGC). The mode of action, however, remained elusive. In the present study, we …
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts
BP Sharpe, A Hayden, A Manousopoulou, A Cowie… - Cell Reports …, 2022 - cell.com
The chemotherapy resistance of esophageal adenocarcinomas (EACs) is underpinned by
cancer cell extrinsic mechanisms of the tumor microenvironment (TME). We demonstrate …
cancer cell extrinsic mechanisms of the tumor microenvironment (TME). We demonstrate …
RETRACTED: Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo …
NA Alhakamy, UA Fahmy, OAA Ahmed - Pharmaceutics, 2019 - mdpi.com
The FDA has approved tadalafil (TDL) for the treatment of benign prostatic hyperplasia
(BPH)-associated symptoms. Pumpkin seed oil (PSO) has shown promise for the relief of …
(BPH)-associated symptoms. Pumpkin seed oil (PSO) has shown promise for the relief of …
Phosphodiesterase 5 (PDE5) is highly expressed in cancer-associated fibroblasts and enhances breast tumor progression
S Catalano, S Panza, G Augimeri, C Giordano… - Cancers, 2019 - mdpi.com
The overexpression of phosphodiesterase (PDE) 5 is frequently found in various human
cancers, such as those of the breast. However, PDE5's role in the tumor microenvironment is …
cancers, such as those of the breast. However, PDE5's role in the tumor microenvironment is …
Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease
Background Myofibroblast transformation is a key step in the pathogenesis of Peyronie's
disease (PD). Phosphodiesterase type 5 inhibitors (PDE5is) and selective estrogen receptor …
disease (PD). Phosphodiesterase type 5 inhibitors (PDE5is) and selective estrogen receptor …
Therapeutic targeting of redox signaling in myofibroblast differentiation and age‐related fibrotic disease
N Sampson, P Berger… - Oxidative medicine and …, 2012 - Wiley Online Library
Myofibroblast activation plays a central role during normal wound healing. Whereas
insufficient myofibroblast activation impairs wound healing, excessive myofibroblast …
insufficient myofibroblast activation impairs wound healing, excessive myofibroblast …
Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease
N Sampson, P Berger… - BioMed Research …, 2014 - Wiley Online Library
Degenerative fibrotic diseases encompass numerous systemic and organ‐specific
disorders. Despite their associated significant morbidity and mortality, there is currently no …
disorders. Despite their associated significant morbidity and mortality, there is currently no …